Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy is a research paper published in Clinical Kidney Journal (2020). On theSindex it has a DataRank of 0. It has been cited 44 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01-DK077162
NIDDK NIH HHS
Grant: R01 DK077162
National Institutes of Health
Grant: 5R01DK077162-07
The Biology of NBCe1 in Health and Disease
Family Foundation and the Ralph Block Family Foundation
Allan Smidt Charitable Fund
Factor Family Foundation and the Ralph Block Family Foundation
FWCI
4.07
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
Additional file 1 of Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
Additional file 1 of Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study
Additional file 1 of Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study
Additional file 2 of Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study
Additional file 2 of Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study
Additional file 3 of Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study
Additional file 3 of Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study